Previous 10 | Next 10 |
Immunic to Participate in Scientific and Industry Conferences in October PR Newswire NEW YORK , Oct. 4, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology th...
Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects PR Newswire – Unblinded Data Revealed a Favorable Safety, Tolerability and Pharmacokinetic Profile for IMU...
Immunic, Inc. to Participate in Investor Conferences in September PR Newswire NEW YORK , Sept. 1, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology the...
Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium PR Newswire NEW YORK , Aug. 16, 2022 ...
Immunic, Inc. (IMUX) Q2 2022 Earnings Conference Call August 4, 2022 08:00 ET Company Participants Jessica Breu - Head, Investor Relations and Communications Daniel Vitt - Chief Executive Officer and President Glenn Whaley - Chief Financial Officer Hella Kohl...
The following slide deck was published by Immunic, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Immunic, Inc. 2022 Q2 - Results - Earnings Call Presentation
Immunic press release ( NASDAQ: IMUX ): Q2 GAAP EPS of -$0.72 in-line. Cash and Cash Equivalents as of Q2 $88.1 million. For further details see: Immunic GAAP EPS of -$0.72 in-line
Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire – Initial Clinical Activity Results of IMU-935 in Psoriasis Expected in the Fourth Quarter – – Unblinded Safety Data from the Single and M...
Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference PR Newswire NEW YORK , Aug. 2, 2022 /PRNewswire/ -- I mmunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selectiv...
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on August 4, 2022 – NEW YORK , July 28, 2022 /PRNewswire/ -- ...
News, Short Squeeze, Breakout and More Instantly...
Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President,...
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...